映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 09-04 16:08:03

180.700

-2.800

-1.53%

最高188.800	最低179.000	成交量71.82万
今开187.100	昨收183.500	日振幅5.34%
总市值164.12亿	流通市值164.12亿	总股本9,082万
成交额1.31亿	换手率0.79%	流通股本9,082万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":180.7,"timestamp":1788509283009,"preClose":183.5,"halted":0,"volume":718164,"delay":0,"changeRate":-0.015258855585831125,"floatShares":90824200,"shares":90824200,"eps":-46.51670051040009,"marketStatus":"已收盘","change":-2.8,"latestTime":"09-04 16:08:03","open":187.1,"high":188.8,"low":179,"amount":131210391,"amplitude":0.053406,"askPrice":181,"askSize":300,"bidPrice":180.7,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-18.833582357938646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":183.5,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.657191,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606/wiki","defaultTab":"wiki","newsList":[{"id":"1157586803","title":"映恩生物-B更新8月股份变动月报表，注册股本维持20,000美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157586803","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157586803?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:54","pubTimestamp":1788512040,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年9月4日发布截至2026年8月31日的月度股份变动报告。公告显示，公司法定/注册股本维持在200,000,000股普通股不变，每股面值0.0001美元，总额20,000美元，未见调整。截至2026年8月31日，公司已发行股份从月初的90,824,214股增至90,833,614股，新增9,400股；库存股份数目则维持在400,100股不变。报告期末已发行股份总数为91,233,714股，符合相应的公众持股量要求。公告显示，公司重申将继续遵守香港联合交易所有限公司《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824188","title":"港股异动 | 映恩生物-B(09606)午后涨超6% BD合作交易总规模超70亿美元 公司探索转为在美共同开发方","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824188","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664824188?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:58","pubTimestamp":1788418738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B午后涨超6%。截至发稿，涨5.74%，报186.1港元，成交额1.43亿港元。华创证券发布研报称，映恩已与国内外7家全球制药公司和创新药企就6个分子及DUPAC创新载荷平台达成合作/合作披露交易总金额超70亿美元，目前仅收到约5.5亿美元首付款与里程碑款项，超65亿美金未确认里程碑收入及药物上市后高个位数至低双位数的销售分成为后续持续现金流流入提供坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","LU2543165471.USD","HK0000252152.HKD","HK0000500386.USD","BK4588","BK1161","BK4585","HK0000252160.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185103683","title":"异动解读｜映恩生物-B盘中上涨5.45%，多家机构维持买入评级叠加超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1185103683","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185103683?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:29","pubTimestamp":1788416991,"startTime":"0","endTime":"0","summary":"9月3日，映恩生物-B盘中上涨5.45%，报185.6港元/股，成交额1.23亿港元。消息面上，招银国际9月2日发布研报维持公司\"买入\"评级，目标价284.50港元，继续看好核心管线Elfe-D在mCRPC领域的重磅潜力。此前瑞银亦首次覆盖给予\"买入\"评级，目标价320港元，东吴证券、招商证券等机构同步看多。此前公司因中期业绩营收同比大幅下滑、经调整净利转亏等因素，股价连续两日累计跌超10%，本次上涨或与多家机构看多共振下的超跌修复有关。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物获多家机构看多，股价超跌反弹上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896872","title":"【券商聚焦】招银国际维持映恩生物（09606）“买入”评级 继续看好Elfe-D在mCRPC领域的重磅潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896872","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664896872?lang=zh_cn&edition=full","pubTime":"2026-09-02 13:10","pubTimestamp":1788325841,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，继续认为，DB-1311/BNT324 是映恩生物最核心的价值驱动，看好其在mCRPC领域的重磅品种潜力。核心管线方面，该机构继续认为mCRPC仍是Elfe-D最重要的估值锚点。ve mCRPC患者、对比docetaxel的全球Phase 3研究，临床推进进一步提速。继续看好Elfe-D在mCRPC领域的重磅潜力，以及ADC + IO2.0联合策略带来的增量空间。考虑到B7-H3 ADC赛道竞争加剧，该机构将公司目标价下调至284.50港元，维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990427","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113854323","title":"异动解读｜映恩生物-B盘中下跌7.29%，上半年营收大幅缩水且经调整净利转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1113854323","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113854323?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:05","pubTimestamp":1788159916,"startTime":"0","endTime":"0","summary":"8月31日，映恩生物-B盘中下跌7.29%，报185.6港元/股，成交额2.82亿港元。经调整净利润由上年同期盈利1.46亿元转为亏损6.27亿元，经营现金流从流入5.90亿元转为净流出4.24亿元，研发开支同比增长73.64%至6.07亿元。此外，生物科技板块整体承压，信达生物跌3.91%，康方生物跌5.24%，百济神州跌3.92%，三生制药跌4.25%，云顶新耀跌6.41%，行业情绪偏弱进一步加剧个股跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"映恩生物盘中异动，营收骤降净利转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064730","title":"映恩生物-B(09606.HK)发布中期业绩，研究与开发开支6.07亿元 同比增加73.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064730","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662064730?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:50","pubTimestamp":1787914238,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2543165471.USD","HK0000500386.USD","09606","HK0000252152.HKD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149809359","title":"映恩生物-B2026年上半年营收2.19亿元 经调整净亏损6.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149809359","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149809359?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:37","pubTimestamp":1787913436,"startTime":"0","endTime":"0","summary":"映恩生物-B在公告中披露，截至2026年6月30日止六个月，公司实现营收2.19亿元，较上年同期的12.29亿元出现大幅下滑。管理层表示，主要由于行使DB-1311/BNT324美国市场独家成本及利润/亏损分担选择权时产生一次性影响，使收入扣减约2.91亿元，同时期内可确认的首付款及里程碑收入也同比减少。非公认会计准则口径（经调整）净利润方面，由上年同期的1.46亿元转为亏损6.27亿元。经营活动现金流从去年同期流入5.90亿元转为本期净流出4.24亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物-B2026年上半年营收2.19亿元 经调整净亏损6.27亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109370447","title":"映恩生物-B携手基因泰克，基于DUPAC新型载荷平台共研下一代抗体偶联药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1109370447","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109370447?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:10","pubTimestamp":1787890236,"startTime":"0","endTime":"0","summary":"映恩生物-B近日宣布，已与罗氏旗下基因泰克达成一项全球合作与许可协议。双方将依托映恩生物自主研发的DUPAC创新载荷平台，共同推进新一代抗体偶联药物的研发工作。这一合作标志着映恩生物在ADC领域的创新实力获得国际制药巨头的认可。映恩生物此次与基因泰克的联手，不仅为其技术平台提供了国际化验证机会，也为公司未来管线拓展奠定了坚实基础。随着更多类似合作的落地，国内ADC药物研发水平有望迈上新台阶。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09606","LU2543165471.USD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662053254","title":"映恩生物-B午前涨近6% 与罗氏集团旗下Genentech签署合作许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2662053254","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662053254?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:49","pubTimestamp":1787888940,"startTime":"0","endTime":"0","summary":"映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。Genentech将获得合作所产生的ADC的全球独家许可，并于第1a期临床开发完成后，Genentech将独自承担进一步临床开发及商业化的责任。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-28/doc-inipvvzv8928555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000500386.USD","BK1161","LU2543165471.USD","09606","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662305899","title":"港股异动 | 映恩生物-B(09606.HK)早盘涨超5% 与Genentech订立ADC合作 潜在里程碑金额超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662305899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662305899?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:35","pubTimestamp":1787884530,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2543165471.USD","09606","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105333233","title":"异动解读｜映恩生物-B盘中上涨5.27%，与Genentech达成全球ADC研发合作获4500万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1105333233","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105333233?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:34","pubTimestamp":1787880852,"startTime":"0","endTime":"0","summary":"8月28日，映恩生物-B盘中上涨5.27%，报203.8港元/股，成交额2801.37万港元。消息面上，公司宣布与罗氏集团成员公司Genentech签订全球研发合作及许可协议，基于公司专有的DUPAC新型有效载荷平台开发下一代抗体偶联药物，用于若干肿瘤适应症。根据协议，映恩生物将主导发现及早期全球临床开发，第1a期临床完成后Genentech获得全球独家许可并负责后续开发与商业化，公司将获得4500万美元首付款。DUPAC平台涵盖DUP5、DUP9及DUP10等多种有效载荷，各具独特抗肿瘤机制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物上涨，ADC合作获4500万美元首付款","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662882037","title":"港股公告掘金 | 蜜雪集团上半年实现收入约152.16亿元 同比增长2.3% 全球门店网络持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2662882037","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662882037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:05","pubTimestamp":1787879123,"startTime":"0","endTime":"0","summary":"重大事项：和黄医药(00013)：爱领达(凡瑞格拉替尼)获中国国家药监局批准用于治疗FGFR2融合/重排的肝内胆管癌患者映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC石四药集团(02005)已取得国家药监局有关钆布醇注射液(7.5ml：4.5354g)的药品生产注册批件固生堂(02273)：收购YC TCM (TAMA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","VXUS","BK1616","02273","BK1588","09606","BK4588","HK0000252160.HKD","KCAI","LU2543165471.USD","HK0000500386.USD","BK1191","BK4585","00013","BK1161","BK1219","02005","BK1233","HK0000252152.HKD","LU2460026573.USD","02097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034349","title":"映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034349","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034349?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:58","pubTimestamp":1787875127,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 发布公告，于2026年8月27日，本公司与罗氏集团成员公司Genentech, Inc.订立合作及许可协议，以基于本公司专有的映恩独特有效载荷抗体偶联平台开发针对若干肿瘤适应症的下一代抗体偶联药物。Genentech将获得合作所产生的ADC的全球独家许可，并于第1a期临床开发完成后，Genentech将独自承担进一步临床开发及商业化的责任。DUPAC涵盖多种有效载荷，包括DUP5、DUP9及DUP10，每种均通过独特的抗肿瘤机制发挥作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","09606","HK0000500386.USD","BK1161","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105788915","title":"映恩生物-B与Genentech就DUPAC平台达成全球ADC研发合作 首付款4,500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105788915","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105788915?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:25","pubTimestamp":1787873143,"startTime":"0","endTime":"0","summary":"2026年8月27日，映恩生物-B公告称，公司已与罗氏集团成员公司Genentech, Inc.签订全球研发合作及许可协议，合作开发基于其专有DUPAC新型有效载荷平台的下一代抗体偶联药物，用于若干肿瘤适应症。根据协议条款，映恩生物-B将主导合作项目的发现及早期全球临床开发；在第1a期临床开发完成后，Genentech将获得合作产生ADC的全球独家许可，并负责后续临床开发及商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137704341","title":"映恩生物-B（Dualitybio-B）达成合作协议，将获4500万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1137704341","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137704341?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:21","pubTimestamp":1787872884,"startTime":"0","endTime":"0","summary":"映恩生物-B（Dualitybio-B）近日宣布，根据一项新签署的合作协议，公司将获得一笔高达4500万美元的首期付款。这一里程碑式的进展，不仅彰显了公司在生物医药领域的创新实力，也为其后续研发管线注入了强劲动力。协议的达成，标志着映恩生物-B在对外合作战略上迈出了坚实一步，有望进一步加速其候选药物的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133605867","title":"映恩生物-B与基因泰克达成全球研发合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1133605867","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133605867?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:20","pubTimestamp":1787872833,"startTime":"0","endTime":"0","summary":"映恩生物-B宣布，已与基因泰克签署一项全球研究、开发合作及许可协议。此举标志着双方在生物医药领域的深度携手，为创新疗法的研发注入了新的动力。协议涵盖的范围广泛，旨在共同推进相关项目的临床前与临床阶段研究，并赋予基因泰克在全球范围内的商业化权利。这一合作不仅彰显了映恩生物-B在抗体药物偶联物等前沿技术领域的研发实力，也为其国际化战略迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","09606","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152991073","title":"映恩生物-B与Genentech达成全球独家许可协议，合作开发抗体偶联药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1152991073","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152991073?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:20","pubTimestamp":1787872809,"startTime":"0","endTime":"0","summary":"映恩生物-B（DUALITYBIO-B）宣布，Genentech将获得双方合作研发的抗体偶联药物（ADC）的全球独家许可权。这一举措标志着两家公司在肿瘤治疗领域的战略合作迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","09606","LU2543165471.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187275425","title":"异动解读｜映恩生物-B盘中上涨5.12%，创新药板块活跃叠加中期业绩临近催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1187275425","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187275425?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:11","pubTimestamp":1787623904,"startTime":"0","endTime":"0","summary":"8月25日，映恩生物-B盘中上涨5.12%，报199.2港元/股，成交额2571.37万港元。消息面上，港股创新药板块整体活跃，国证港股通创新药指数上涨，板块内云顶新耀、荣昌生物等多股走强，映恩生物-B跟随板块共振。公司层面，瑞银近日首次覆盖给予\"买入\"评级，目标价320港元，较当前股价存在显著上行空间；招商证券、东吴证券、中国银河证券此前亦先后首次覆盖并给予积极评级。此外，公司将于8月28日披露中期业绩，叠加此前持续回购动作，机构看多情绪与业绩释放预期形成短期催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物盘中上涨，创新药板块共振催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161459117","title":"异动解读｜映恩生物-B盘中上涨5.22%，瑞银首次覆盖叠加中期业绩临近催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1161459117","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161459117?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:37","pubTimestamp":1787279870,"startTime":"0","endTime":"0","summary":"8月21日，映恩生物-B盘中上涨5.22%，报197.5港元/股，成交额4669.57万港元。消息面上，瑞银近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价320港元，较当前股价存在约62%的上行空间。此外，招商证券、东吴证券、中国银河证券此前亦先后首次覆盖并给予积极评级。同时，公司将于8月28日披露中期业绩，叠加此前持续回购动作，机构看多情绪与业绩释放预期形成共振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物获瑞银首次看好，中期业绩临近催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100329397","title":"财报前瞻｜映恩生物-B回购与中期业绩临近，机构看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1100329397","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100329397?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:35","pubTimestamp":1787279724,"startTime":"0","endTime":"0","summary":"映恩生物-B将于2026年8月28日盘后披露中期业绩，市场关注现金消耗与商业化推进节奏对收入与利润曲线的影响。目前缺少可验证的一致性季度预测，工具层面未提供本季度营收、毛利率、净利润或净利率、调整后每股收益的具体预测与同比数据。在可获得的机构研报与观点中，看多意见占比更高，占比100.00%。结合公司在2026年5月的回购举措与8月28日中期业绩披露的临近时间点，该机构倾向于将资本动作与业绩释放的潜在协同视作估值的催化因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜映恩生物-B回购与中期业绩临近，机构看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0614},{"period":"1month","weight":-0.0347},{"period":"3month","weight":-0.0166},{"period":"6month","weight":-0.4186},{"period":"1year","weight":-0.5035},{"period":"ytd","weight":-0.3846}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}